I pay $9.99 US per trade  Scotia iTRDAE. However, paying $50/trade only increases 1 to 2 cents per share if let's say one invests a capital of $500. In the long run that may be worth it. I bought as high as 30 cents and as low as 5 cents US.

Zenith may have a better chance of success, in my opinion.

OPDIVO + YERVOY seems to be a success for Bristol Myers Squibb. If Apabetalone adds benefit to the O+Y combination, this may finally give way for a Zenith IPO.

Koo